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Abstract
Neuroblastoma is a cancer of the developing sympathetic nervous system that most com-
monly presents in young children and accounts for approximately 12% of pediatric oncology
deaths. Here, we report on a genome-wide association study (GWAS) in a discovery cohort
or 2,101 cases and 4,202 controls of European ancestry. We identify two new association
signals at 3q25 and 4p16 that replicated robustly in multiple independent cohorts comprising
1,163 cases and 4,396 controls (3q25: rs6441201 combined P = 1.2x10-11, Odds Ratio
1.23, 95% CI:1.16–1.31; 4p16: rs3796727 combined P = 1.26x10-12, Odds Ratio 1.30, 95%
CI: 1.21–1.40). The 4p16 signal maps within the carboxypeptidase Z (CPZ) gene. The 3q25
signal resides within the arginine/serine-rich coiled-coil 1 (RSRC1) gene and upstream of
the myeloid leukemia factor 1 (MLF1) gene. Increased expression of MLF1 was observed in
neuroblastoma cells homozygous for the rs6441201 risk allele (P = 0.02), and significant
growth inhibition was observed upon depletion of MLF1 (P < 0.0001) in neuroblastoma cells.
Taken together, we show that common DNA variants within CPZ at 4p16 and upstream of
MLF1 at 3q25 influence neuroblastoma susceptibility and MLF1 likely plays an important
role in neuroblastoma tumorigenesis.
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Author summary
Neuroblastoma is an embryonal tumor of the developing sympathetic nervous system that
accounts for 12% of childhood cancer deaths. Approximately 1–2% of cases are inherited
in an autosomal dominant fashion. These familial cases often harbor germline mutations
in ALK or PHOX2B. However, the vast majority of neuroblastomas appear to arise sporad-
ically. We are studying sporadic neuroblastoma through an ongoing genome-wide associ-
ation study (GWAS). To date, this effort has identified single nucleotide polymorphisms
(SNPs) within or upstream of CASC15 and CASC14, BARD1, LMO1, DUSP12, HSD17B12,
DDX4/IL31RA,HACE1, LIN28B, and TP53, along with a common copy number variation
(CNV) within NBPF23 at chromosome 1q21.1, each being highly associated with neuro-
blastoma. Here, we report on genome-wide association study (GWAS) comprising 3,264
neuroblastoma patients and 8,598 control subjects. We identify two new association sig-
nals at 3q25 and 4p16 (3q25: rs6441201 combined P = 1.2x10-11, Odds Ratio 1.23, 95%
CI:1.16–1.31; 4p16: rs3796727 combined P = 1.26x10-12, Odds Ratio 1.30, 95% CI: 1.21–
1.40). The 3q25 signal resides upstream of the MLF1 gene and the 4p16 signal maps to the
CPZ gene. We further demonstrate that neuroblastoma cells homozygous for the risk
allele at 3q25 express higher levels of MLF1 and that silencing of MLF1 in neuroblastoma
cells results in significant growth inhibition.
Introduction
Neuroblastoma is a cancer of the developing sympathetic nervous system that most commonly
affects children under 5 years of age, with a median age at diagnosis of 17 months [1]. Approx-
imately 50% of cases present with disseminated disease at the time of diagnosis, and despite
intense multi-modal therapy, the survival rate for this high-risk subset remains less than 50%
[1]. Somatically acquired segmental DNA copy number alterations, such as MYCN amplifica-
tion and deletions of 1p and 11q, are associated with aggressive disease and poor survival [2].
However, recent whole genome and exome sequencing studies have revealed a relative paucity
of somatic point mutations in neuroblastoma tumors [3–6].
In terms of the etiology of neuroblastoma, only 1–2% of patients present with a family his-
tory of disease; the vast majority of cases appear to arise sporadically. Familial neuroblastoma
is largely explained by germline mutations in ALK [7, 8] or PHOX2B [9, 10]. To understand
the genetic basis of sporadic neuroblastoma, we are performing a genome-wide association
study (GWAS). To date, this effort has identified single nucleotide polymorphisms (SNPs)
within or upstream of CASC15 [11, 12] and CASC14 [11], BARD1 [13, 14], LMO1 [15], DUSP12
[16], HSD17B12 [16], DDX4/IL31RA [16], HACE1 [17], LIN28B [17], and TP53 [18], along with
a common copy number variation (CNV) within NBPF23 [19] at chromosome 1q21.1, each
being highly associated with neuroblastoma. Importantly, several of the neuroblastoma suscepti-
bility genes identified by GWAS have been shown to not only influence disease initiation, but
also drive tumor aggressiveness and/or maintenance of the malignant phenotype [15, 17, 20–22].
Here, to identify additional germline variants and genes influencing neuroblastoma tumori-
genesis, we imputed genotypes across the genome (see Methods) and performed a discovery
GWAS of genotyped and imputed variants in a cohort of 2,101 neuroblastoma patients and
4,202 control subjects of European ancestry [17]. This effort refined previously reported sus-
ceptibility loci and identified two new association signals at 3q25 and 4p16 which were repli-
cated in three independent cohorts comprising 1,163 cases and 4,396 controls. In addition,
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based on expression quantitative trait loci (eQTL) analysis and in vitro studies following
manipulation of candidate genes in neuroblastoma cell lines, we demonstrate that the 3q25 sig-
nal likely targets the myeloid leukemia factor 1 (MLF1) gene in neuroblastoma, resulting in
increased MLF1 expression and promoting cell growth.
Results
Discovery GWAS based on individuals of European ancestry
To discover germline variants associated with neuroblastoma, we performed a GWAS follow-
ing genome-wide genotype imputation in 2,101 neuroblastoma patients accrued through the
North American-based Children’s Oncology Group (S1 Table) and 4,202 control subjects of
European ancestry (see Methods; S1 Fig)[17]. Individuals were genotyped using the Illumina
HumanHap550 or Quad610 Beadchip. Multi-dimensional scaling was used to infer ancestry,
and the first twenty components were recorded for subsequent use as co-variates in association
testing to control for potential population substructure. To generate imputed genotypes, we
first selected SNPs present on both platforms that passed our quality control metrics and
applied SHAPEIT to infer haplotypes[23]. We then utilized IMPUTE2 [24] with default
parameters and Ne = 20000, along with a multi-population reference panel from the world-
wide 1000 Genomes Project Phase 1 Release 3 to impute genotypes across the entire genome.
For quality control purposes, variants with minor allele frequency (MAF) <1% and/or IMPU-
TE2-info quality score <0.7 were removed following imputation. The remaining variants were
tested for association with neuroblastoma using the frequentist association test under the addi-
tive model using the “score” method implemented in SNPTEST [25] (Fig 1 and S2 Fig). The
genomic inflation factor was 1.04 (S3 Fig).
Refinement of known neuroblastoma susceptibility loci
We first confirmed previous reports of neuroblastoma-associated loci, and identified variants
of greater statistical significance through imputation at each locus (Fig 2; S2–S8 Tables). Spe-
cifically, we observed association at 2q35 implicating BARD1 [13] (Fig 2A, rs58430496: p =
3.05 x 10−11; OR: 1.36, 95% CI: 1.25–1.48), 6p22 implicating CASC15 [11], (Fig 2B, rs4712656:
p = 8.07 x 10−16; OR: 1.37, 95% CI: 1.27–1.47), and 6q16-q21 implicating HACE1 [17] (Fig 2C,
rs72990858: p = 1.37 x 10−13; OR: 0.59, 95% CI: 0.51–0.69). After conditioning on rs72990858
at 6q16, we identified a second independent association signal at 6q16-q21 implicating LIN28B
[17] (Fig 2D, rs17065417: p = 4.72 x 10−9; OR: 0.70, 95% CI: 0.62–0.80). We also confirmed
association at 11p15 implicating LMO1 [15] (Fig 2E, rs2168101: p = 3.18 x 10−16; OR: 0.70,
95% CI: 0.70–0.65), 11p11 implicating HSD17B12 [16] (Fig 2F, rs10742682: p = 1.31 x 10−7;
OR: 1.24, 95% CI: 1.15–1.34) 17p13 implicating TP53 [18] (Fig 2G, rs35850753: p = 1.39 x
10−8; OR: 1.95, 95% CI: 1.57–2.43).
Discovery of new neuroblastoma susceptibility loci at 3q25 and 4p16
We observed two new genome-wide significant associations, the first at 3q25 (rs6441201:
p = 3.01 x 10−7; Odds Ratio: 1.21, 95% C.I.: 1.12–1.30; Fig 3A; Table 1; S9 Table) and the other
at 4p16 (rs3796727: p = 5.25 x 10−9; Odds Ratio: 1.26, 95% C.I.: 1.16–1.36; Fig 3B; Table 1; S10
Table). The novel association signal at 3q25 spans a large 470-Kb linkage disequilibrium (LD)
block in the HapMap CEU population, encompasses the arginine/serine-rich coiled-coil 1
(RSRC1) gene, and maps just upstream of the myeloid leukemia factor 1 gene (MLF1) (Fig
3A). The signal at 4p16 marks an approximate 27.5-Kb LD block in the CEU population and
maps within the carboxypeptidase Z (CPZ) gene (Fig 3B).
Neuroblastoma susceptibility loci at 3q25 and 4p16
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Functional annotation of neuroblastoma-associated variants
To identify potential causal variants at each susceptibility locus, we developed an annotation
tool incorporating data from ENCODE [26], the Roadmap Epigenomics Project [27], evolu-
tionary conservation, and transcription factor binding motifs (see Methods). We applied this
tool to all variants with a discovery p-value < 10−4, MAF > 0.005, and info score > 0.5. This
approach confirmed the recently identified causal variant (rs2168101) at the LMO1 locus
shown to disrupt a canonical GATA binding site in neuroblastoma[20], and identified several
other variants that warrant further study. (S2–S10 Tables).
Conditional, interaction, and clinical correlative analyses
To investigate whether more than one association signal may exist at 3q25 or 4p16, we condi-
tioned our analysis of 3q25 on rs6441201 and our analysis of 4p16 on rs3796727. No evidence
for a separate association signal was observed at either locus (S4 Fig). In addition, no associa-
tion was observed between rs6441201 or rs3796727 genotypes and clinical/biological covari-
ates, including markers of tumor aggressiveness (S11 and S12 Tables). An interaction analysis
between rs6441201 or rs3796727 and the most statistically significant SNPs at each of the pre-
viously reported susceptibility loci revealed only weak evidence for epistasis (S13 Table), sug-
gesting that these loci may contribute independently to neuroblastoma risk.
Replication of 3p25 and 4p16 association signals in three independent
cohorts
We next sought to replicate the new 3q25 and 4p16 association signals in three independent
cohorts (S2 Fig). First, we analyzed an African American cohort of 365 neuroblastoma cases
and 2,491 genetically matched controls [28]. These individuals were genotyped on the Illumina
HumanHap550 or Quad-610 bead chips, and SHAPEIT and IMPUTE2 [24] were applied to
infer genotypes at the 3q25 and 4p16 loci using data from the 1000 Genomes Phase I Release 3
in a manner similar to the European American cohort. Utilizing the proportion of African
Fig 1. Manhattan plot of discovery results. Level of significance (-log10 transformed P values) for each SNP
along the genome in chromosomal order is plotted. Red line: significance threshold of 5.0 x 10−8 considered for
identification of novel loci. Previously identified susceptibility loci are labeled; new association signals identified
at chromosomes 3q25 and 4p16 are indicated in bold.
https://doi.org/10.1371/journal.pgen.1006787.g001
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Fig 2. Genome-wide imputation confirms previously reported neuroblastoma susceptibility loci and identifies additional variants
of greater statistical significance. Regional association plots of genotyped and imputed SNPs at previously reported neuroblastoma
susceptibility loci identified by GWAS. Plots generated using LocusZoom. Y-axes represent the significance of association (-log10
Neuroblastoma susceptibility loci at 3q25 and 4p16
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admixture as a covariate to correct for varying degrees of admixture among our samples, we
confirmed the association of rs6441201 at 3q25 (p = 5.70 x 10−3; Odds Ratio: 1.23, 95% CI:
1.04–1.45; Table 1; S5 Fig). Genotype imputation at the 4p16 locus was of low confidence in
this cohort and therefore was not included. Next, we performed PCR-based genotyping in
two additional independent cohorts for the top genotyped SNP at 3q25 (rs6441201), and two
SNPs at the 4p16 locus since they were imputed (rs3796727 and rs3796725). First, we geno-
typed an Italian cohort of 427 neuroblastoma cases and 783 controls and observed a trend
toward association in the same direction seen in the European and African American samples
at 3q25 (rs6441201: P = 0.11, OR: 1.15, 95% CI: 0.97–1.36) and a robust replication at 4p16
(rs3796727: P = 0.010, OR: 1.28, 95% CI: 1.07–1.54; rs3796725: P = 4.36 x 10−3, OR: 1.33, 95%
CI: 1.01–1.61 Table 1). Second, we genotyped both SNPs in a cohort of 371 cases and 1,122
controls from the United Kingdom, and confirmed all associations (rs6441201: P = 8.45 x
10−4, OR: 1.32, 95% CI: 1.12–1.56; rs3796727: P = 1.71 x 10−3, OR: 1.33, 95% CI: 1.11–1.59;
transformed P values) and recombination rate. SNPs are color-coded based on pair-wise linkage disequilibrium (r2) with the most statistically
significant SNP. (a) 2q35 locus implicating BARD1 (rs58430496: p = 3.05 x 10–11; OR: 1.36, 95% CI: 1.25–1.48) (b) 6p22 locus implicating
CASC15 (rs4712656: p = 8.07 x 10–16; OR: 1.37, 95% CI: 1.27–1.47) (c) 6q16-q21 locus implicating HACE1 (rs72990858: p = 1.37 x 10–13;
OR: 0.59, 95% CI: 0.51–0.69) (d) independent association at 6q16-q21 after conditioning on rs72990858 implicates LIN28B (rs17065417:
p = 4.72 x 10–9; OR: 0.70, 95% CI: 0.62–0.80) (e) 11p15 locus implicating LMO1 (rs2168101: p = 3.18 x 10–16; OR: 0.70, 95% CI: 0.70–0.65)
(f) 11p11 locus implicating HSD17B12 (rs10742682: p = 1.31 x 10–7; OR: 1.24, 95% CI: 1.15–1.34) and (g) 17p13 implicating TP53
(rs35850753: p = 1.38 x 10–8; OR: 1.95, 95% CI: 1.57–2.43).
https://doi.org/10.1371/journal.pgen.1006787.g002
Fig 3. Discovery of neuroblastoma susceptibility loci at chromosome 3q25 and 4p16. Regional association plots of genotyped and imputed SNPs
novel susceptibility loci. Plots were generated using LocusZoom. Y-axes represent the significance of association (-log10 transformed P values) and the
recombination rate. SNPs are color-coded based on pair-wise linkage disequilibrium (r2) with indicated SNPs (a) 3q25 locus: rs6441201 shown in purple
(3.01 x 10−7; Odds Ratio: 1.21, 95% C.I.: 1.12–1.30). (b) 4p16 locus: rs3796727 shown in purple (p = 5.25 x 10−9; Odds Ratio: 1.26, 95% C.I.: 1.16–1.36).
https://doi.org/10.1371/journal.pgen.1006787.g003
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rs3796725: P = 0.028, OR: 1.23 95% CI: 1.02–1.48; Table 1). Meta-analysis using the inverse-
variance method within METAL[29] resulted in a highly significant associations with neuro-
blastoma (Table 1; rs6441201: P = 1.21x10-11, Odds Ratio 1.23, 95% CI:1.16–1.31 and
rs3796727: P = 126x10-12, Odds Ratio 1.30, 95% CI:1.21–1.40; rs3796725: P = 2.08 x 10−11,
Odds Ratio 1.29, 95% CI:1.19–1.38).
rs3796727 genotype correlates with methylation status of CPZ at 4p16
To investigate whether the neuroblastoma susceptibility variants may function as methylation
quantitative trail loci (meQTL), we performed a methylation genome-wide association study
based on additive risk genotype of rs6441201 (3q25) or rs3796727 (4p16) in a cohort of 769
individuals without cancer for whom we have both SNP and methylation array data, as
described previously [30]. Briefly, M-values (log2 ratio between the methylated and unmethy-
lated probe intensities [31]) were compared using an additive model based on SNP genotype.
Principal component analysis (PCA) was first applied to infer ancestry (S6 Fig), and we
focused initially on 395 individuals of European ancestry. No evidence was observed for
rs6442101 functioning as a meQTL in this cohort. However, in our analysis of rs3796727 geno-
types, we observed a single genome-wide significant meQTL signal mapping to the same
Table 1. Statistically significant and replicated SNP associations at 3q25 and 4p16.
SNP Major
Allele




P-value‡ OR§ (95% CI║)
rs6441201 G A European
American
0.52 (n = 2,101) 0.47 (n = 4,202) 3.01 x 10−7 1.21 (1.12–
1.30)
African American 0.68 (n = 365) 0.64 (n = 2,491) 5.70 x 10−3 1.23 (1.04–
1.45)
United Kingdom 0.54 (n = 371) 0.47 (n = 1,122) 8.45 x 10−4 1.32 (1.12–
1.56)






rs3796725 C T European
American
0.35 (n = 2,101) 0.31 (n = 4,202) 1.41 x 10−8 1.23 (1.15–
1.34)
United Kingdom 0.33 (n = 353) 0.29 (n = 1,057) 0.028 1.23 (1.02–
1.48)






rs3796727 G A European
American
0.35 (n = 2,101) 0.30 (n = 4,202) 5.25 x 10−9 1.26 (1.16–
1.36)
United Kingdom 0.35 (n = 362) 0.29 (n = 1,094) 1.71 x 10−3 1.33 (1.11–
1.59)






† No deviations from Hardy-Weinberg equilibrium were observed (P>0.001) in all cohorts.
‡Allelic P-values; combined P-values from meta-analysis using METAL.
§OR: Odds Ratio with respect to the minor (risk) allele.
║CI: Confidence Interval
https://doi.org/10.1371/journal.pgen.1006787.t001
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neuroblastoma-associated locus at 4p16 (cg14339343, p = 1.33 x 10−16; S7 Fig; S14 Table); this
signal replicated in the independent cohort comprised of 332 individuals of African ancestry
(cg14339343, p = 1.36 x 10−6 S8 Fig; S15 Table). Analyzing all 769 individuals together in a
multi-ethnic meGWAS yielded a highly significant association between rs3796727 genotype
and methylation status of cg14339343 (cg14339343, p = 5.98 x 10−21 Fig 4A; S16 Table). Closer
examination revealed that this meQTL resides directly within the 50 UTR of the CPZ gene (Fig
4B), and the rs3796727 risk allele is associated with decreased methylation (Fig 4C, S9 Fig).
These data suggest that rs3796727 genotype may influence CPZ expression. While RNA was
not available to assess CPZ expression in these individuals, interrogation of the Genotype-Tis-
sue Expression (GTEx) Portal revealed that CPZ expression was primarily limited to ovary,
cervix and fallopian tube (S10 Fig). Cervix and fallopian tube did not include matched geno-
type data and thus eQTL analysis was not possible, but ovary tissue showed increased CPZ
expression in cells homozygous for the rs3796727 risk allele (p = 0.17; S11 Fig). While not
reaching statistical significance, this trend is consistent with the observed genotype-methyla-
tion correlation. Taken together, these data suggest that rs3796727 genotype may be associated
Fig 4. Methylation genome-wide association study (meGWAS) identifies rs3796727 as a methylation quantitative trait loci (meQTL)
for sites in CPZ. (a) Manhattan plot of meGWAS results in 793 individuals based on additive rs3796727 genotype. A single genome-wide
significant association is identified and the most statistically significant methylation probe is labeled (cg14339343). (b) LocusZoom plot at 4p16
locus reveals cg14339343 maps to the CPZ gene. Y-axes represent the significance of association (-log10 transformed P values) and the
recombination rate. (c) Box plot of M-values based on rs3796727 genotype in 793 individuals. The rs3796727 risk allele “A” is associated with
decreased methylation.
https://doi.org/10.1371/journal.pgen.1006787.g004
Neuroblastoma susceptibility loci at 3q25 and 4p16
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with decreased methylation and increased CPZ expression; further study is necessary to con-
firm this role for rs3796727 in neuroblastoma directly.
rs6441201 at 3q25 is a multi-tissue expression quantitative trait loci
(eQTL)
To determine if the neuroblastoma-associated SNPs at 3q25 are eQTLs, we utilized the GTEx
Portal. The rs6441201 variant at 3q25 was identified as a multi-tissue cis-eQTL for both RSRC1
(p = 1.05 x 10−78; S12 Fig) and LOC100996447, a recently discovered long non-coding RNA
located at 3q25 (p = 1.14 x 10−145; S13 Fig). In addition, rs6441201 was identified as a cis-
eQTL for MLF1 in esophagus (p = 6.33 x 10−11; S14 Fig).
rs6441201 risk alleles are associated with increased MLF1 expression
and MLF1 silencing results in decreased cell growth in neuroblastoma
cells
We next analyzed a set of 19 neuroblastoma cell lines with matched genome-wide SNP geno-
typing and mRNA expression data. The rs6441201 variant was not observed to be an eQTL for
RSRC1 in neuroblastoma cells. However, MLF1 expression was significantly higher in neuro-
blastoma cells harboring the rs6441201 risk allele compared those homozygous for the protec-
tive allele (P = 0.02; Fig 5A). We further interrogated seven additional genes in the region, but
did not observe association of rs6441201 genotype with mRNA levels. Consistent with these
findings, silencing of MLF1, but not RSRC1, using pooled siRNA resulted in significant cell
growth inhibition in neuroblastoma cells (Fig 5A–5D).
Discussion
Neuroblastoma is an embryonal tumor of the autonomic nervous system thought to arise from
developing and incompletely committed precursor cells derived from neural crest tissues; it
is the most common cancer diagnosed in the first year of life [1]. Here, in order to identify
germline genetic risk factors and genes influencing neuroblastoma tumorigenesis, we per-
formed a genome-wide association studying (GWAS) comprising a total of 3,264 neuroblas-
toma patients and 8,598 healthy control subjects from four independent cohorts. Two new
neuroblastoma susceptibility loci were identified, one at chromosome 3q25 and the other at
4p16. The 4p16 variants map to the CPZ gene locus, and the 3q25 variants map within RSRC1
and upstream of MLF1.
The CPZ gene encodes a member of the carboxypeptidase E subfamily of metallocarboxy-
peptidases which represent Zn-dependent enzymes implicated in intra- and extracellular
processing of proteins. Through an unbiased meGWAS, we observed strong evidence for
rs3796727 functioning as a meQTL for sites within the 50 UTR of CPZ. Specifically, the
rs3796727 risk allele was associated with decreased methylation, suggesting the risk allele
may be associated with increased expression of CPZ. CPZ is a Zn-dependent enzyme with an
N-terminal cysteine-rich domain (CRD) and a C-terminal catalytic domain. CPZ is enriched
in the extracellular matrix and expressed during early embryogenesis. In addition to contain-
ing a metallocarboxypeptidase domain, CPZ also contains a Cys-rich domain with homology
to Wnt-binding proteins [32]. Indeed, studies in chick embryos suggest that CPZ is involved
in WNT signaling[33]. In addition, CPZ has been shown to modulate Wnt/beta-catenin signal-
ing and terminal differentiation of growth plate chondrocytes[34]. Among the tissues interro-
gated in GTEx, CPZ expression was primarily observed in ovary, where there was a trend
toward increased expression in cells homozygous for the risk allele (S10 and S11 Figs). Our
Neuroblastoma susceptibility loci at 3q25 and 4p16
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Fig 5. rs6441201 risk allele at 3q25 correlates with increased MLF1 expression and MLF1 silencing results in decreased
cell growth in neuroblastoma cells. (a) MLF1 mRNA expression is significantly higher in neuroblastoma cell lines harboring
one or more copies of the rs6441201 risk allele (A) compared to neuroblastoma cell lines homozygous for the protective allele
(GG). (b) Silencing of RSRC1 or MLF1 expression using pooled siRNAs resulted in 50–90% reduced mRNA levels by real-time
quantitative PCR in neuroblastoma cell lines. (c) Confirmation by Western blot of knockdown at the protein level for RSRC1 and
MLF1 after siRNA mediated silencing in neuroblastoma cell lines. (d-g) siRNA mediated silencing of MLF1 results in significant
growth inhibition of neuroblastoma cells compared to non-targeting control siRNA; no effect was observed upon silencing of
RSRC1. Cell growth measured by real-time cell sensing system (RT-ces).
https://doi.org/10.1371/journal.pgen.1006787.g005
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methylation GWAS based on additive risk allele at the 4p16 susceptibility locus revealed signif-
icantly decreased methylation in the 5’ UTR of CPZ of cells harboring the risk allele, consistent
with increased CPZ expression. Matched RNA was not available to assess mRNA expression in
the methylation GWAS cohort, and a genotype-expression correlation was not observed in
neuroblastoma cell lines. However, CPZ may influence tumor initiation and thus require
assessment of precursor cells from the developing sympathetic nervous system.
The 3q25 variants map within RSRC1 which encodes a member of the serine and arginine
rich-related protein family. The gene product has been shown to play a role in constitutive and
alternative splicing, and is involved in the recognition of the 30 splice site during the second
step of splicing [35]. Variants in RSRC1 are associated with the neurological disease schizo-
phrenia, and RSRC1 is involved in prenatal brain development and cell migration to forebrain
structures [36]. RSRC2, a member of the same gene family, has been proposed as a tumor
suppressor gene in esophageal carcinogenesis[37]. Increased expression of RSRC2 has been
observed in neuroblastomas harboring somatic gain of chromosome 12q [38], and a MIER2-
RSRC1 fusion has been observed in prostate cancer [39]. Taken together, existing studies sug-
gest that RSRC1 may play an important role in both neural stem cell proliferation and cancer
development.
The MLF1 gene, also mapped to 3q25, encodes an oncoprotein that is thought to play a role
in the phenotypic determination of hematopoetic cells. It was first identified as the C-terminal
partner of the leukemic fusion protein nucleophosmin (NPM)-MLF1 that resulted from a t
(3;5)(q25.1;q34) chromosomal translocation [40]. MLF1 is overexpressed in more than 25% of
MDS-associated cases of AML, in the malignant transformation phase of MDS, and in lung
squamous cell carcinoma [41, 42]. MLF1 overexpression is thought to suppress a rise in the
CDK inhibitor CDKN1B, preventing the activation of Epo-activated terminal differentiation
pathway and promoting proliferation [43]. MLF1 is expressed in a wide variety of tissues, shut-
tles between the cytoplasm and the nucleus, and has also been shown to reduce proliferation
by stabilizing the activity of TP53 by suppressing its E3 ubiquitin ligase, COP1 [44]. These data
suggest that MLF1 may play both a tumor suppressing and an oncogenic role depending on
the biological context.
Since both RSRC1 and MLF1 have been previously implicated in cancer, we investigated the
3q25 locus in more detail. Based on GTEx data, rs6441201 is a multi-tissue eQTL for both
RSRC1 and a recently discovered long non-coding RNA LOC100996447at 3q25. While we did
not observe a genotype-expression correlation for RSRC1 or LOC100996447 in neuroblastoma
cells, we cannot rule out the possibility that variants at 3q25 influence expression of RSRC1
and/or LOC100996447genes early in tumorigenesis within developing neural crest cells. How-
ever, MLF1 expression was observed in nineteen distinct neuroblastoma cell lines interrogated
in this study, with the highest expression in cells homozygous for the risk allele at rs6441201.
Silencing of MLF1 resulted in significant growth inhibition in four distinct neuroblastoma cell
lines. Taken together, these data are consistent with the hypothesis that MLF1 promotes neuro-
blastoma tumorigenesis, and that the 3q25 risk alleles are associated with growth advantage
through increased MLF1 expression. Given that the observed cell growth phenotype was inde-
pendent of rs6441201 genotype, alternative mechanisms driving MLF1 expression to promote
neuroblastoma cell growth likely exist.
In conclusion, here we refine previously reported susceptibility loci, identify common vari-
ation at chromosome 3q25 and 4p16 associated with neuroblastoma, and provide insight into
potential causal variants at the newly identified susceptibility loci. The newly associated vari-
ants at 4p16 are located within CPZ, and the top associated SNP is a meQTL for sites located
directly within the 50 UTR of CPZ. The associated variants at 3q25 appear to function in cis to
alter MLF1 expression in neuroblastoma. Based on initial functional studies, it is likely that
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germline susceptibility alleles at 3q25 play and important role in both initiation and disease
progression. Ongoing studies will further elucidate the role of both CPZ and MLF1 in neuro-
blastoma tumorigenesis.
Materials and methods
Genotype imputation and association testing
A primary European-American cohort of 2,101 cases and 4,202 matched controls were assayed
with Illumina HumanHap550 v1, Illumina HumanHap550 v3, and Illumina Human610 SNP
arrays as previously described [17]. Genotypes were phased using SHAPEIT [23] v2.r790
and data from 1000 Genomes Phase 1 Release 3. Subsequently, imputation was performed
genome-wide using IMPUTE2 [24] v2.3.1 for all SNPs and indel variants annotated in 1000
Genomes Phase I Release 3. To minimize potential errors in phasing and imputation per-
formed genome-wide, we employed a genome-tiling approach. Each position in the genome
was covered by a minimum of three tiles (sliding windows). Variants with MAF <1% and/or
IMPUTE2-info quality score <0.7 were removed. Testing for association with neuroblastoma
was performed under an additive genetic effect model using the frequentist likelihood score
method implemented in SNPTEST [25] v2.4.1. After genome-wide assessment, regions with
p< 5.0 x 10−7 were re-imputed without tiling and tested for association in a similar manner.
Genotypes for a previously described African-American replication cohort of 365 cases 2491
controls [28] were imputed and tested for neuroblastoma association using the same analytic
pipeline. Statistical adjustment for gender was performed in both cohorts. For population
stratification adjustment, the first 20 multidimensional scaling (MDS) components were
included as covariates in the European-American cohort, while a measure of African admix-
ture as estimated by the ADMIXTURE software program was used in the African-American
cohort.
Replication in Italian and United Kingdom cohorts
Genotyping of the top associated SNPs at MLF1 (rs6441201) and RSRC1 (rs3796725 and
rs3796727) was performed using TaqMan SNP genotyping assays (Life Technology). The
Italian cohort was comprised of a total of 432 neuroblastoma cases and 780 controls. The
replication cohort from the United Kingdom included 371 cases and 1,122 controls in total.
Association with neuroblastoma was assessed using an additive genetic effect model of the fre-
quentist likelihood score method implemented in SNPTEST [25] v2.4.1 in the same manner as
the discovery cohort.
Genotype imputation and methylation association testing
DNA from 769 children without cancer was extracted from blood and genotyped using Illu-
mina HumanHap550 v1, Illumina HumanHap550 v3, and Illumina Human610 SNP arrays.
DNA from the same individuals was also profiled for genome-wide methylation using Illumina
450K methylation arrays. Genotypes were phased using SHAPEIT [23] v2.r790 and data from
1000 Genomes Phase 1 Release 3. Subsequently, imputation was performed genome-wide
using IMPUTE2 [24] v2.3.1 for all SNPs and indel variants annotated in 1000 Genomes Phase
I Release 3. Principal component analysis (PCA) was performed based on genotype data and
ancestry was inferred. A threshold of 0.9 was applied to rs3796727 imputed genotype probabil-
ities for the purpose of methylation association testing; genotypes from individuals not reach-
ing this threshold were excluded. Association testing was subsequently performed using linear
regression with the R software.
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Meta-analysis
Meta-analysis was performed using the inverse-variance method within the METAL [29] soft-
ware package, and a fixed-effects model was assumed.
Methylation data analyses
Genome-wide methylation profiles were generated from gDNA isolated from peripheral blood
mononuclear cells from a total of 854 subjects recruited by the Center for Applied Genomics
(CAG) at the Children’s Hospital of Philadelphia (CHOP) on the Infinium HumanMethyla-
tion450 BeadChip Kit according to the manufacturers’ protocols. and analyzed as Methylation
data were exported from GenomeStudio and subjected to quantile color balance adjustment,
background level correction, and simple scaling normalization as described previously [30]. Prin-
ciple component analysis identified 425 subjects of European ancestry, 374 African Americans,
20 East Asians, and 24 Hispanics among these subjects. Methylation probes known to overlap
with common SNPs, were identified and removed using the IMA R package. M-values (the log2
ratio between the methylated and unmethylated probe intensities) were extracted and stored as a
matrix. Additive genotypes at rs3796727 for subjects of European ancestry were extracted from
existing genotyping data using PLINK. There are a total of 402 subjects of European ancestry
without missing genotype at rs3796727 and extreme outlier values of methylation M-values
(median M-value of the genotype group±3 s.d.). Methylation data in gene CPZ were analyzed
as the response variable in a linear regression, with genotype at as the predictor variable among
these 402 subjects. Sex, age, and 10 genotype-derived principle components were included as
covariates. Linear regression and generation of boxplots was performed using base packages in R.
Genome-wide mRNA expression profiling of neuroblastoma cell lines
Genome-wide mRNA expression profiling in neuroblastoma cell lines was performed using
the Illumina WG-6 expression array according to the manufacturer’s specifications. Data were
normalized using the average normalization method provided in Illumina GenomeStudio soft-
ware. ANOVA test was performed at the gene level to assess differential expression in cell
lines. P< 0.05 was considered significant. Data is available from the Gene Expression Omni-
bus (GEO) database (Accession: GSE78061).
RT-PCR in neuroblastoma cell lines
TaqMan Gene expression assays for MLF1 (Hs00963682_m1), RSRC1 (HS00963694_m1) and
HPRT (Hs02800695_m1) were purchased through Life Technologies. Reactions were set up in
triplicate. Starting with 200 ng RNA, reverse transcription was performed followed by 1:4 dilu-
tion and 2 ul of cDNA was subsequently used in a 10-μl reaction with 1× TaqMan Universal
PCR Master Mix (Life Technologies). Standard curves were generated using serial dilutions of
cDNA from the neuroblastoma cell line Kelly, produced in the same RT reaction as the experi-
mental samples. Samples were amplified on an Applied Biosystems 7900HT Sequence Detec-
tion System using standard cycling conditions, and data were collected and analyzed with SDS
2.3 software. MLF1 and RSRC1 expression levels were normalized to HPRT expression.
MLF1 and RSRC1 protein detection
Neuroblastoma cell lines were grown in T75 flasks under standard cell culture conditions.
Cells were plated into 6 well plates for transfection with siRNA, 2 wells per target for protein
analysis. Replicate samples were pooled on collection. Whole-cell lysates were extracted with
100 μl of protein lysis buffer containing Tris Base (25mM), NaCl (150 mM), EGTA and EDTA
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(1 mM each), NaF (10 mM) DTT (1 mM), Triton X-100 (1%), and protease/phosphatase
inhibitors (Cell Signaling, #5872) on ice for at least 30 minutes before brief sonication. After
15 min of centrifugation at 4˚C, the supernatant was removed, and protein quantification was
performed using the Pierce BCA Protein Assay Kit (Life Technologies, 23225). Lysates (12 μg)
were separated on 10% Criterion TGX gels (BioRad) and were transferred to PVDF mem-
branes. Membranes were washed and incubated with antibodies directed against MLF1
(Abcam, ab70211), RSRC1 (Abcam, ab106650) and Ku80 (Cell Signaling, 2753). All blocking
and antibody dilution was performed in 5% milk in TBST.
MLF1 and RSRC1 knockdown and monitoring of cell growth
For routine maintenance, cells were grown in RPMI 1640 complete medium (Gibco, 22400)
containing 10% FBS (Hyclone, SH 30073–03), 1× antibiotic antimycotic (Gibco, 15240–062)
and 2 mM l-glutamine (Gibco, 25030). On day 0, cells were seeded in triplicate into antibiotic-
free medium in 96-well RT-CES plates (ACEA). On day 1, using DharmaFECT 1 (Dharmacon,
T-2001-03, 0.1%), cells were transiently transfected with 25 nM of either a non-targeting nega-
tive control siRNA (Dharmacon, D-00810-10-20) or pooled siRNA directed against MLF1 (L-
019478-00-0005) or RSRC1 (L-028584-01-0005). Real-time cell growth was monitored every
hour for at least 96 h using the RT-CES system, as previously described. Data presented are
representative of at least three independent experiments. To monitor efficiency of MLF1 and
RSRC1 knockdown, transfection was performed as described, and RNA was isolated 48 hours
later using the Qiagen mini extraction kit. Total RNA (200 ng) was primed with oligo(dT) and
reverse transcribed using SuperScript First Strand Synthesis System for RT-PCR (Life Tech-
nologies). Quantitative RT-PCR using TaqMan gene expression assays (ABI) was performed
as described above. Similarly, protein was isolated 72 hours after transfection to monitor
MLF1 and RSRC1 protein knockdown using Western blot analysis as described.
GWAS annotation tool
Variants directly genotyped, or imputed from the 1000 Genomics phase 1 release 3 data with
discovery p-value < 10−4, MAF > 0.005, and info score > 0.5 were annotated and ranked
based on a DNase I hypersensitivity data, evolutionary conservation, transcription factor bind-
ing site scores, and Roadmap Epigenomics data. Conservation scores were computed as the
average of the phastCons46way Placental UCSC conservation track score for all bases from the
−10 position to the +10 position surrounding each candidate variant. A DNase I hypersensitiv-
ity score was calculated by counting the number of sequencing tags from the −100 position to
the +100 position around each candidate variant in ENCODE data for the neuroblastoma cell
line, SK-N-SH. Scanning for transcription factor binding motifs was performed using a cus-
tom implementation of the MATCH algorithm[45] using JASPAR 2014[46] position weight
matrices (PWMs) as input. Briefly, to quantify the conservation of position i in a PWM











and a normalized matrix similarity score (mSS) was computed as previously described.
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This scan was completed both for the entire human reference genome (hg19) and a modi-
fied version of the reference genome (hg19_alt), where each reference base was replaced by its
alternative base at each SNP position. A match was called for a PWM if the mSS was greater
than 0.8 for either hg19 or hg19_alt at a given position overlapping a SNP. At these positions,
an mSS difference (delta-nrm) and an absolute score difference (delta-abs) were computed
between hg19_alt and hg19 as two separate metrics to quantify the predicted effect of each
SNP on transcription factor binding.
Web resources
The URLs for data presented herein are as follows:








S1 Table. Neuroblastoma patient characteristics.
(PDF)
S2 Table. SNPTEST results at 2q35 NB susceptibility locus in European American Discov-
ery Cohort (2,101 cases; 4,202 controls).
(XLSX)
S3 Table. SNPTEST results at 6p22 NB susceptibility locus in European American Discov-
ery Cohort (2,101 cases; 4,202 controls).
(XLSX)
S4 Table. SNPTEST results at 6q16-q21 NB susceptibility locus in European American Dis-
covery Cohort (2,101 cases; 4,202 controls).
(XLSX)
S5 Table. SNPTEST results at 6q16-q21 NB susceptibility locus conditioned on rs72990858
in European American Discovery Cohort (2,101 cases; 4,202 controls).
(XLSX)
S6 Table. SNPTEST results at 11p15 NB susceptibility locus in European American Dis-
covery Cohort (2,101 cases; 4,202 controls).
(XLSX)
S7 Table. SNPTEST results at 11p11 NB susceptibility locus in European American Dis-
covery Cohort (2,101 cases; 4,202 controls).
(XLSX)
S8 Table. SNPTEST results at 17p13 NB susceptibility locus in European American Dis-
covery Cohort (2,101 cases; 4,202 controls).
(XLSX)
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S9 Table. SNPTEST results at novel 3q25 NB susceptibility locus in European American
Discovery Cohort (2,101 cases; 4,202 controls).
(XLSX)
S10 Table. SNPTEST results at novel 4p16 NB susceptibility locus in European American
Discovery Cohort (2,101 cases; 4,202 controls).
(XLSX)
S11 Table. Correlation of rs6442101 genotype with clinical variables.
(PDF)
S12 Table. Correlation of rs3796727 genotype with clinical variables.
(PDF)
S13 Table. Epistasis analysis results.
(PDF)
S14 Table. European American methylation GWAS results at 4p16 locus based on additive
rs3796727 genotype.
(XLSX)
S15 Table. African American methylation GWAS results at 4p16 locus based on additive
rs3796727 genotype.
(XLSX)
S16 Table. Combined European and African American methylation GWAS results at 4p16
locus based on additive rs3796727 genotype.
(XLSX)
S1 Fig. MDS plot of discovery and replication cohorts. a. European-ancestry discovery
cohort. b. African American replication cohort.
(PDF)
S2 Fig. Flow diagram of discovery and replication efforts. Shown are the Discovery and Rep-
lication cohorts utilized in this study along with ancestry information and the number of vari-
ants tested. Two novel loci were replicated, including a single genotyped variant from 3q25
(rs6442101) and two variants from 4p16 (rs3796725 and rs3796727). Variants located at 4p16
were not imputed in Replication Cohort #1 (African American) with acceptable quality, and
therefore were not considered. These variants, along with rs6442101 at 3q25, were directly
genotyped using a PCR-based approach in Replication cohorts #2 and #3.
(PDF)
S3 Fig. QQ plot of discovery GWAS. Plotted are the expected vs. observed–log10 p-values
from the European ancestry discovery cohort. Genomic inflation factor was 1.04.
(PDF)
S4 Fig. Conditional association results. Genomic position based on hg19. a. conditioned on
rs6442101. The original signal is completely ablated, and a putative second signal of modest
statistical significance is observed downstream of MLF1. b. conditioned on rs3796727. SNPs
mapping to the 4p16 susceptibility locus are no longer statistically significant indicating a sin-
gle association signal.
(PDF)
S5 Fig. LocusZoom plot of 3q25 locus in African American replication cohort. Regional
association plot of genotyped and imputed SNPs at 3q25 locus. Y-axes represent the
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significance of association (-log10 transformed P values) and the recombination rate. SNPs are
color-coded based on pair-wise linkage disequilibrium (r2) with indicated SNPs at q25 locus:
rs6441201 shown in purple (p = 5.70 x 10−3; Odds Ratio: 1.23, 95% CI: 1.04–1.45).
(PDF)
S6 Fig. PCA of individuals considered for methylation GWAS. Green: European ancestry.
Black: African ancestry. Red: Asian ancestry.
(PDF)
S7 Fig. Manhattan plot of European American methylation GWAS. Association of
rs3796727 with cg14339343 methylation status is confirmed when restricting to individuals of
European ancestry (p = 1.33 x 10−16). See S14 Table for detailed methylation GWAS results at
the 4p16 locus.
(PDF)
S8 Fig. Manhattan plot of African American methylation GWAS. Association of rs3796727
with cg14339343 methylation status is confirmed when restricting to individuals of African
ancestry (p = 1.36 x 10−6). See S15 Table for detailed methylation GWAS results at the 4p16
locus.
(PDF)
S9 Fig. Risk allele at rs3796727 is associated with decreased methylation at CPZ. M-value
for cg14339343, located in 50 UTR of CPZ, is plotted based on additive rs3796727 risk allele
(0,1,or 2 alleles). (a) Plot restricted to children of European ancestry. (b) Plot restricted to chil-
dren of African American ancestry.
(PDF)
S10 Fig. CPZ expression across normal tissues in GTEx. CPZ exhibits tissue specific expres-
sion. CPZ is primarily expressed in Ovary. CPZ is also expressed in mammary tissue, cervix
(ecto and endo), mucosa in esophagus, fallopian tube, and vagina. Minimal or no expression is
observed in remaining tissues profiled.
(PDF)
S11 Fig. Expression of CPZ in ovarian tissue. Expression of CPZ is higher in ovarian tissue
homozygous for the rs3796727 neuroblastoma-associated risk allele at 4p16, though this did
not reach statistical significance (p = 0.17). Data and figure from GTEx portal (Analysis
Release V6).
(PDF)
S12 Fig. rs6441201 is a multi-tissue eQTL for RSRC1. Expression of RSRC1 is significantly
correlated with rs6441201 genotype. Data and figure from GTEx portal (Analysis Release V6).
(PDF)
S13 Fig. rs6441201 is a multi-tissue eQTL for LOC100996447. Expression of LOC100996447
(RP11-538P18.2), a long non-coding RNA, is significantly correlated with rs6441201 genotype.
Data and figure from GTEx portal (Analysis Release V6).
(PDF)
S14 Fig. rs6441201 is an eQTL for MLF1 in esophagus. Expression of MLF1 is significantly
correlated with rs6441201 genotype in esophagus mucosa (p = 6.3 x 10−11). Data and figure
from GTEx portal (Analysis Release V6).
(PDF)
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